Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 622

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 622
---
 |         |   |
| Operating lease obligation - current                |     | $                             | 143,396 |   |
| Operating lease obligation - net of current portion |     |                               |  52,956 |   |
| Total operating lease obligation                    |     | $                             | 196,352 |   |

Note 8 – Contribution and Exchange Agreement

On August 7, 2022, the Company and each of its shareholders entered into a Contribution and Exchange Agreement (the “C&E Agreement”) with Longevity, a related party (see Note 4). In connection with the signing of the C&E Agreement, Longevity entered into similar agreements with Aegeria Soft Tissue LLC, and Novokera, LLC (collectively, along with Cerevast, the “Target Companies”). Upon the consummation of the transactions contemplated by the C&E Agreement and the agreements with the other Target Companies (collectively the “Acquisition Transactions”), the Target Companies will be acquired by Longevity.

The consummation of the Acquisition Transactions is conditioned upon the satisfaction or waiver of certain closing conditions including the entering into and subsequent closing of an approved business combination agreement with a blank-check special purpose acquisition company.

The parties to the C&E Agreement have made customary representations and warranties and have also agreed to certain customary covenants with respect to, among others, the conduct of the business of Cerevast and Longevity prior to the closing of the Acquisitions Transactions.

| F-100 |

<div align='center'>CEREVAST MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS (UNAUDITED)</div>

First Amendment to the C&E Agreement

On January 25, 2023, the Company and each of its shareholders entered into an amendment to the C&E Agreements with Longevity pursuant to which certain provisions of the C&E Agreements were amended to, among other things: modify the aggregate valuation assigned to Longevity reflecting the Acquisition Transactions, modify the allocation of the transaction consideration among the Target Companies, modify the minimum cash balance at closing of the Business Combination, and modify certain representations, warranties, covenants, closing conditions, termination provisions, and other provisions of the C&E Agreements.

Second Amendment to the C&E Agreement

On June 26, 2023 the C&E Agreements were further amended to revise the definition of an Approved deSPAC Transaction to have a lock-up of 180 days for directors, officers and 5% or greater stockholders of